Glaukos Corporation reported strong first quarter 2026 growth but remains unprofitable. Net sales reached $150.6 million, up 41% year-over-year, driven mainly by glaucoma products, including U.S. Glaucoma revenue of $93.5 million and growing adoption of the iDose TR therapy.
GAAP gross margin was about 78%, with non-GAAP gross margin near 84%. The company posted a GAAP net loss of $19.8 million, or ($0.34) per share, and a non-GAAP net loss of $10.4 million, or ($0.18) per share. Glaukos ended the quarter with $280.5 million in cash, equivalents, short-term investments and restricted cash and no debt, and raised its 2026 net sales guidance to $620–$635 million.
Vanguard Portfolio Management reports beneficial ownership of 3,256,962 shares of Glaukos Corp common stock, representing 5.6% of the class as of 03/31/2026. The filer discloses sole dispositive power over 3,256,962 shares and sole voting power for 48,599 shares. The statement was filed as a Schedule 13G and signed on 04/29/2026.
Glaukos Corporation has issued its 2026 proxy statement for the May 28, 2026 virtual annual meeting, asking stockholders to elect two Class II directors, approve executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor.
For 2025, Glaukos reports net sales of $507 million and cash, equivalents, restricted cash and short-term investments of $283 million as of December 31, 2025. The eight‑member board is 88% independent, 38% women, and 25% from underrepresented communities, with an average age of 60.6 years and average tenure of 12.6 years.
The proxy highlights say‑on‑pay support of 97.7% at the 2025 meeting, a pay program emphasizing variable, performance‑linked compensation, stock ownership and clawback policies, and strong governance practices including overboarding limits, an updated code of conduct, active cybersecurity oversight, and expanding sustainability and climate initiatives.
Glaukos Corp’s chief development officer, Tomas Navratil, sold 2,093 shares of common stock in open‑market trades. The sales on April 10, 2026 were executed at prices ranging from about $116.72 to $120.23 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 12, 2026.
After these transactions, Navratil directly holds 90,370 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered. The filing notes that several trades were executed in multiple lots, with the reported prices reflecting weighted averages.
Glaukos Corporation submitted a Form 144 notice disclosing proposed sales of Common Stock by an affiliate through broker Fidelity Brokerage Services LLC. The filing lists past sales of 1,031 shares on 03/16/2026 for $101,085.67 and identifies restricted stock vesting events of 338, 517, and 1,238 shares on 12/13/2024, 12/18/2024, and 01/01/2025, respectively.
Glaukos Corp’s Chief Development Officer Tomas Navratil reported a routine tax-withholding disposition of 2,977 shares of common stock. The issuer withheld 1,146 shares and 1,831 shares at $109.60 per share to cover tax obligations upon vesting and delivery of restricted stock units granted in 2022 and 2024.
After these withholdings, Navratil directly owns 92,463 shares of common stock. His position also reflects 43,483 restricted stock units from the March 24, 2022 grant and 39,791 restricted stock units from the March 14, 2024 grant that have not yet vested or been delivered.
GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,589 shares of common stock to satisfy his tax withholding obligations.
After this non-market transaction, Thurman directly holds 43,681 shares of common stock. Footnotes also state he has 5,230 restricted stock units that have not yet vested or been delivered, indicating additional potential future equity awards.
GLAUKOS Corp president and COO Joseph E. Gilliam reported a routine tax-withholding share disposition tied to equity compensation. On the vesting and delivery of previously granted restricted stock units, 3,169 shares of common stock were withheld by the company at $109.60 per share to cover his tax obligations.
After this non-market transaction, he directly holds 92,992 shares of GLAUKOS common stock, including 43,925 restricted stock units that have not yet vested or been delivered. The filing does not reflect an open-market purchase or sale, but rather the automated tax treatment of stock-based compensation.
Glaukos Corp chairman and CEO Thomas William Burns reported non-market changes in his holdings. He transferred 180,308 shares of common stock as a bona fide gift from his direct ownership to the Burns Family Trust. Separately, a total of 9,937 shares were withheld by Glaukos at a price of $109.60 per share to satisfy his tax withholding obligations upon vesting and delivery of previously granted restricted stock units.
Following these transactions, Burns continues to hold common stock directly and indirectly through several trusts, and some of these positions include restricted stock units that have not yet vested or been delivered.